The high expression of CTLA-4 in tumor-infiltrating Treg cells and the presence of innate effector cells expressing high levels of CD16 and CD32a activatory FcγRs both in mouse and humans likely explain the preferential local depletion in the tumor by both antibody isotypes. The gene discussed is FCGR3A; the disease is neoplasm.